Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: Theoretical consideration and therapeutic potential

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1221-1227

  Mikhail, Nasser ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Dipeptidyl peptidase inhibitors; Incretins; Pioglitazone; Sitagliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; VILDAGLIPTIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN ANALYSIS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG EDEMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; POSTPRANDIAL STATE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADAMANTANE; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; EDEMA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; NITRILES; PYRAZINES; PYRROLIDINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIAZOLES;

EID: 60249089873     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Ahren B, Gomis R, Standl B, et al. 2004. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 27:2874-80.
2. Ahren B. 2008. Novel combination treatment of type 2 diabetes: DPP-4 inhibition + metformin. Vasc Health Risk Manag, 4:382-94.
3. Aschner P, Kipnes MS, Lunceford JK, et al. 2006. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 29:2632-7.
4. Azuma K, Radikova Z, Mancino J, et al. 2008. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab, 93:459-64.
5. Bolen S, Feldman L, Vassy J, et al. 2007. Systemic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med, 147:386-99.
6. Budde K, Neumayer H, Fritsche L, et al. 2003. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol, 55:368-74.
7. Chan JC, Scott R, Ferreira A, et al. 2008. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab, 10:545-55.
8. Dormandy JA, Charbonnel B, Eckland DJA. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomized controlled trial. Lancet, 366:1279-89.
9. Drucker DJ, Nauck MA. 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368:1696-705.
10. Garber AJ, Schweizer A, Baron A, et al. 2007. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab, 9:166-74.
11. Garber AJ, Foley JE, Banerji A, et al. 2008. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab.
12. Goke B, Hershon K, Kerr D, et al. 2008. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res.
13. Goldstein BJ, Feinglos MN, Lunceford JK, et al. 2007. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care, 30:1979-87. Erratum: Diabetes Care, 2008; 31:1713.
14. Hanefeld M, Herman GA, Wu M, et al. 2007. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin, 23:1329-1339.
15. Januvia® (sitagliptin phosphate) package insert. 2007. Merk and Co., Inc., Whitehouse Station, NJ 08889, USA.
16. Kermani A, Garg A. 2003. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc, 78:1088-91.
17. Manley HJ, Allock NM. 2003. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherpay, 23:861-5.
18. Mikhail N. 2006. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J, 99:1271-9.
19. Mikhail N, Cope D. 2007. The role of DPP-4 inhibitors in type 2 diabetes. Patient Care, August: 18-24.
20. Mikhail N. 2008. Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs, 17:845-53.
21. Nathan DM, Buse JB, Davidson M, et al. 2006. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 29:1963-72.
22. Nauck MA, Meininger G, Sheng D, et al; for the Sitagliptin Study 024 Group. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab, 9:194-205.
23. Pi-Sunyer FX, Schweizer A, Mills D, et al. 2007. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract, 76: 132-8.
24. Pratley RE, Jauffret-Kamel S, Galbreath B, et al. 2006. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res, 38:423-8.
25. Raz I, Hanefeld M, Xu L, et al; for the Sitagliptin Study 023 Group. 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 49:2564-71.
26. Rosenstock J, Brazg R, Andryuk PJ, et al; for the Sitagliptin Study 019 Group. 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 28:1556-68.
27. Rosenstock J, Baron MA, Camisasca RP, et al. 2007. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab, 9:175-85.
28. Utzschneider KM, Tong J, Montgomery B, et al. 2008. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care, 31:108-13.
29. Vella A, Bock G, Giesler PD, et al. 2007. Effects of dipeptidyl peptidase inhibition on gastrointestinal function, meal appearanace, and glucose metabolism in type 2 diabetes. Diabetes, 56:1475-80.
30. Vilsboll T, Agerso H, Krarup T, et al. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab, 88:220-4.
31. Yki-Jarvinen H. 2004. Drug therapy: Thiazolidinediones. N Engl J Med, 351:1106-18.